FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2972432710> ?p ?o ?g. }

• W2972432710 endingPage "601" @default.
• W2972432710 startingPage "591" @default.
• W2972432710 abstract "Fibroblast growth factor receptor (FGFR) 2 is overexpressed in several tumor types, including triple-negative breast cancer and gastric cancer, both of which have a high unmet medical need. Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use a novel auristatin-based payload.This first-in-human trial was conducted to determine the safety, tolerability, and maximum tolerated dose (MTD) of aprutumab ixadotin in patients with advanced solid tumors from cancer indications known to be FGFR2-positive.In this open-label, multicenter, phase I dose-escalation trial (NCT02368951), patients with advanced solid tumors received escalating doses of aprutumab ixadotin (starting at 0.1 mg/kg body weight), administered intravenously on day 1 of every 21-day cycle. Primary endpoints included safety, tolerability, and the MTD of aprutumab ixadotin; secondary endpoints were pharmacokinetic evaluation and tumor response to aprutumab ixadotin.Twenty patients received aprutumab ixadotin across five cohorts, at doses of 0.1-1.3 mg/kg. The most common grade ≥ 3 drug-related adverse events were anemia, aspartate aminotransferase increase, proteinuria, and thrombocytopenia. Dose-limiting toxicities were thrombocytopenia, proteinuria, and corneal epithelial microcysts, and were only seen in the two highest dosing cohorts. The MTD was determined to be 0.2 mg/kg due to lack of quantitative data following discontinuations at 0.4 and 0.8 mg/kg doses. One patient had stable disease; no responses were reported.Aprutumab ixadotin was poorly tolerated, with an MTD found to be below the therapeutic threshold estimated preclinically; therefore, the trial was terminated early. CLINICALTRIALS.NCT02368951." @default.
• W2972432710 created "2019-09-19" @default.
• W2972432710 creator A5007299835 @default.
• W2972432710 creator A5008409227 @default.
• W2972432710 creator A5018636031 @default.
• W2972432710 creator A5025451632 @default.
• W2972432710 creator A5026459010 @default.
• W2972432710 creator A5037834137 @default.
• W2972432710 creator A5039492614 @default.
• W2972432710 creator A5062811024 @default.
• W2972432710 creator A5067544331 @default.
• W2972432710 creator A5068520667 @default.
• W2972432710 creator A5072354499 @default.
• W2972432710 creator A5076426660 @default.
• W2972432710 date "2019-09-09" @default.
• W2972432710 modified "2023-10-06" @default.
• W2972432710 title "First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer" @default.
• W2972432710 cites W1499908575 @default.
• W2972432710 cites W1821781403 @default.
• W2972432710 cites W1854073441 @default.
• W2972432710 cites W1930773806 @default.
• W2972432710 cites W1964100609 @default.
• W2972432710 cites W1965509437 @default.
• W2972432710 cites W1968119293 @default.
• W2972432710 cites W1972892632 @default.
• W2972432710 cites W2008680700 @default.
• W2972432710 cites W2011911766 @default.
• W2972432710 cites W2023297465 @default.
• W2972432710 cites W2027505922 @default.
• W2972432710 cites W2043958889 @default.
• W2972432710 cites W2047783656 @default.
• W2972432710 cites W2051889880 @default.
• W2972432710 cites W2062486240 @default.
• W2972432710 cites W2078054478 @default.
• W2972432710 cites W2084762981 @default.
• W2972432710 cites W2095605190 @default.
• W2972432710 cites W2113727201 @default.
• W2972432710 cites W2119420462 @default.
• W2972432710 cites W2124514746 @default.
• W2972432710 cites W2128413110 @default.
• W2972432710 cites W2137881702 @default.
• W2972432710 cites W2139046059 @default.
• W2972432710 cites W2145148317 @default.
• W2972432710 cites W2155256323 @default.
• W2972432710 cites W2159967578 @default.
• W2972432710 cites W2161608625 @default.
• W2972432710 cites W2164337721 @default.
• W2972432710 cites W2202939373 @default.
• W2972432710 cites W2259204994 @default.
• W2972432710 cites W2313476029 @default.
• W2972432710 cites W2315322079 @default.
• W2972432710 cites W2419639370 @default.
• W2972432710 cites W2507779661 @default.
• W2972432710 cites W2537586856 @default.
• W2972432710 cites W2550856922 @default.
• W2972432710 cites W2560286577 @default.
• W2972432710 cites W2566505805 @default.
• W2972432710 cites W2597045666 @default.
• W2972432710 cites W2603088210 @default.
• W2972432710 cites W2626344037 @default.
• W2972432710 cites W2761653596 @default.
• W2972432710 cites W2769124823 @default.
• W2972432710 cites W2774294088 @default.
• W2972432710 cites W2948387511 @default.
• W2972432710 doi "https://doi.org/10.1007/s11523-019-00670-4" @default.
• W2972432710 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6797631" @default.
• W2972432710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31502117" @default.
• W2972432710 hasPublicationYear "2019" @default.
• W2972432710 type Work @default.
• W2972432710 sameAs 2972432710 @default.
• W2972432710 citedByCount "36" @default.
• W2972432710 countsByYear W29724327102020 @default.
• W2972432710 countsByYear W29724327102021 @default.
• W2972432710 countsByYear W29724327102022 @default.
• W2972432710 countsByYear W29724327102023 @default.
• W2972432710 crossrefType "journal-article" @default.
• W2972432710 hasAuthorship W2972432710A5007299835 @default.
• W2972432710 hasAuthorship W2972432710A5008409227 @default.
• W2972432710 hasAuthorship W2972432710A5018636031 @default.
• W2972432710 hasAuthorship W2972432710A5025451632 @default.
• W2972432710 hasAuthorship W2972432710A5026459010 @default.
• W2972432710 hasAuthorship W2972432710A5037834137 @default.
• W2972432710 hasAuthorship W2972432710A5039492614 @default.
• W2972432710 hasAuthorship W2972432710A5062811024 @default.
• W2972432710 hasAuthorship W2972432710A5067544331 @default.
• W2972432710 hasAuthorship W2972432710A5068520667 @default.
• W2972432710 hasAuthorship W2972432710A5072354499 @default.
• W2972432710 hasAuthorship W2972432710A5076426660 @default.
• W2972432710 hasBestOaLocation W29724327101 @default.
• W2972432710 hasConcept C112705442 @default.
• W2972432710 hasConcept C121608353 @default.
• W2972432710 hasConcept C126322002 @default.
• W2972432710 hasConcept C143998085 @default.
• W2972432710 hasConcept C159654299 @default.
• W2972432710 hasConcept C197934379 @default.
• W2972432710 hasConcept C203014093 @default.
• W2972432710 hasConcept C203092338 @default.
• W2972432710 hasConcept C2777325958 @default.

• next